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Mechanisms regulating thrombus stabilization remain largely unknown. Here, we report that loss of any 1 of 
the Gas6 receptors (Gas6-Rs), i.e., Tyro3, Axl, or Mer, or delivery of a soluble extracellular domain of Axl that 
traps Gas6 protects mice against life-threatening thrombosis. Loss of a Gas6-R does not prevent initial platelet 
aggregation but impairs subsequent stabilization of platelet aggregates, at least in part by reducing “outside-
in” signaling and platelet granule secretion. Gas6, through its receptors, activates PI3K and Akt and stimulates 
tyrosine phosphorylation of the β3 integrin, thereby amplifying outside-in signaling via αIIbβ3. Blocking the 
Gas6-R–αIIbβ3 integrin cross-talk might be a novel approach to the reduction of thrombosis.
Introduction
Formation of a platelet plug initiates hemostasis at sites of vas-
cular injury and triggers pathological thrombosis in ischemic tis-
sue disease. After initial formation of a single platelet monolayer, 
additional platelets are recruited into the growing hemostatic plug. 
Without further stabilization, platelet plugs prematurely disaggre-
gate. While platelet plug instability may precipitate rebleeding at 
sites of vascular injury, inhibition of platelet plug stabilization may 
be therapeutically attractive to prevent pathological thrombosis. 
Indeed, agents inhibiting the formation of stable platelet plugs, but 
leaving behind an intact platelet coverage, might block thrombosis, 
possibly without eliciting major adverse bleeding effects. The avail-
ability of such compounds would be desirable, as currently avail-
able antithrombotic agents often cause a bleeding diathesis.
The molecular mechanisms controlling perpetuation of the platelet 
plug are incompletely characterized. The αIIbβ3 integrin plays a central 
role in platelet aggregation. In the initial phase, activation of platelets 
by ADP, thromboxane A2 (TXA2), and thrombin signals “inside-out” 
via αIIbβ3, thereby increasing its ligand binding and activation (1). In 
the perpetuation phase, the activated αIIbβ3 transmits critical “out-
side-in” signals, which commits the platelets to activation, irreversible 
platelet aggregation, and clot retraction (1). A critical signaling event 
includes the phosphorylation of tyrosine residues in the cytoplasmic 
domain of the β3 integrin (2–4). Additional outside-in signaling mol-
ecules include the Eph kinases and ephrins, and CD40 ligand (5, 6).
We recently reported that Gas6 enhances the formation of 
stable platelet macroaggregates in response to various agonists 
(7). Gas6 binds to the receptor tyrosine kinases Tyro3, Axl, and 
Mer via its carboxyterminal globular domain (8–10). Each of the 
Gas6 receptors (Gas6-Rs) has an extracellular ligand-binding 
domain and a cytoplasmic tyrosine kinase domain, the activity 
of which is enhanced by Gas6 (9, 11–17). This then leads to fur-
ther intracellular signaling, including activation of the PI3K and 
Akt pathways (18–20). The Gas6-R–mediated signaling cascades 
in platelets remain unknown. Gas6–/– mice are protected against 
thrombosis but do not suffer from bleeding (7). Mice with a triple 
deficiency of Tyro3, Axl, and Mer have not been reported to exhib-
it abnormal hemostasis under baseline conditions (21), but their 
response in pathological conditions was not evaluated.
In this study, we determined that Gas6, through its receptors, 
activates PI3K and Akt and stimulates tyrosine phosphorylation of 
the β3 integrin, thereby amplifying outside-in signaling via αIIbβ3. 
Furthermore, we established that a “Gas6 trap” prevents patholog-
ical thrombosis, which indicates that this novel cross-talk between 
the Gas6-Rs and αIIbβ3 integrin may constitute a novel target for 
antithrombotic therapies.
Results
Loss of a Gas6-R causes rebleeding and protection against thrombosis. Mice 
lacking any 1 of the Gas6-Rs, i.e., Tyro3–/–, Axl–/–, or Mer–/– mice, 
did not suffer spontaneous bleeding or thrombosis under base-
line conditions. We used 2 bleeding models to investigate the 
effects of loss of any 1 of the Gas6-Rs on hemostasis. In the first 
model, we determined the time to cessation of bleeding. When 
bleeding did not recur within 60 seconds of cessation, bleeding 
was considered to be arrested. All genotypes had normal bleeding 
times after tail clipping: 290 ± 56 seconds for WT mice, 300 ± 32 
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seconds for Tyro3–/– mice, 220 ± 17 seconds for Axl–/– mice, and 
200 ± 36 seconds for Mer–/– mice (mean ± SEM, n = 10, P = NS). As 
the first bleeding model is not suitable to detect rebleeding after 
initial hemostasis, we used a second model where the amount of 
blood loss was estimated every minute for 10 minutes and, there-
after, every 5 minutes until 30 minutes. In WT mice, blood loss 
increased progressively to reach a plateau within 10 minutes, after 
which bleeding stopped completely. In contrast, Tyro3–/–, Axl–/–, or 
Mer–/– mice had a tendency to repetitively rebleed after transient 
hemostasis, as shown by the stepwise increase in blood loss (Figure 
1). Consequently, Gas6-R–deficient mice lost more blood during 
30 minutes after tail clipping than WT mice (95 ± 35 μl in WT 
mice versus 260 ± 66 μl in Tyro3–/– mice, 260 ± 28 μl in Axl–/– mice, 
and 270 ± 60 μl in Mer–/– mice; n = 10, P < 0.05). Similar results 
were obtained in Gas6–/– mice (data not shown).
Two thrombosis models were used to determine the role of 
Tyro3, Axl, or Mer in pathological thrombosis. In the first model, 
thrombosis was induced by ligation of the inferior vena cava fol-
lowed by i.v. injection of tissue thromboplastin. Stasis-induced 
venous thrombosis results from both coagulation and plate-
let activation (22). Compared with WT mice, thrombi in 
Tyro3–/–, Axl–/–, or Mer –/– mice were on average reduced by 
more than 90% (n = 10, P < 0.005; Figure 2A). In the second 
model, platelet-dependent thromboembolism was induced 
by intrajugular injection of collagen and epinephrine and 
caused fatal pulmonary embolism within 5 minutes in 
80% of WT mice (n = 15). In contrast, fatal pulmonary embolism 
was observed, after 10–20 minutes, in only 25% of Tyro3–/– mice 
(n = 15), in 10% of Axl–/– mice (n = 10), and in 20% of Mer –/– mice 
(n = 12, P < 0.05 versus WT for all Gas6-R–/– mice; Figure 2B). 
Macroscopic and histological analysis revealed extensive pulmo-
nary thromboembolism in WT mice (Figure 2C). In contrast, no 
signs of pulmonary embolization were detectable in surviving 
Axl–/– mice (Figure 2D), or in Tyro3–/– or Mer –/– mice (data not 
shown). The hemostatic phenotype of Gas6-R–deficient mice was 
not attributable to genotypic differences in platelet counts, pro-
thrombin and activated partial thromboplastin times, or fibrino-
gen levels (data not shown).
Although the above model of collagen-induced thromboem-
bolism is recognized to be platelet dependent, we sought to fur-
ther confirm that the protection against thrombus formation in 
mice lacking a Gas6-R was predominantly due to altered platelet 
function. We therefore induced thromboembolism with collagen 
and epinephrine in Axl–/– mice after platelet depletion and subse-
quent reconstitution with either WT or Axl–/– platelets (23, 24). 
Thrombocytopenia was achieved in Axl–/– mice by i.p. injection of 
20 mg/kg busulfan on days 1 and 3 and i.v. injection of anti-platelet 
mAb CV-5H7 on day 3 (25). On day 6, platelet counts dropped to 
less than 10 giga/liter (G/l). Thromboembolism experiments were 
performed on day 6 after reconstitution of WT or Axl–/– platelets 
in Axl–/– thrombocytopenic mice (washed platelets from 3 WT or 3 
Axl–/– mice were necessary to reconstitute 1 Axl–/– mouse). Platelet 
counts in Axl–/– mice after reconstitution with WT platelets or Axl–/– 
platelets were 546 ± 45 G/l (n = 5) and 583 ± 39 G/l (n = 5), respec-
tively. Fatal pulmonary embolism was observed in 4 of 5 Axl–/– 
mice reconstituted with WT platelets but, notably, in none of the 
Axl–/– mice reconstituted with Axl–/– platelets. These results confirm 
that resistance of Gas6-R–deficient mice to thromboembolism may 
be largely attributed to a platelet-function defect.
Impaired platelet aggregation and clot retraction in Tyro3–/–, Axl–/–, or 
Mer–/– mice. Since Gas6 impairs platelet plug formation (7), platelet 
function of Gas6-R–deficient mice was also studied. Platelets from 
WT mice dose-dependently aggregated in response to increasing 
concentrations of ADP, collagen, or the TXA2 analogue U46619, 
achieving a maximal effect at concentrations similar to those pre-
viously reported (7). In contrast, platelets from Tyro3–/–, Axl–/–, 
or Mer–/– mice failed to irreversibly aggregate in response to low 
concentrations of ADP (less than 10 μM; Figure 3A), collagen 
Figure 1
Effect of the lack of Tyro3, Axl, or Mer on hemostasis. After 2-mm tail-
tip transection, the cut end of the tail was immersed in saline at 37°C. 
Aliquots of saline solution containing blood were sampled every minute 
for 10 minutes and then every 5 minutes until 30 minutes. The amount 
of blood loss was determined by measurement of the hemoglobin con-
tent of the aliquots of blood collected in saline (mean ± SEM, n = 10). 
In WT mice, blood loss reached a plateau within 10 minutes, indicating 
cessation of bleeding. In contrast, Tyro3–/–, Axl–/–, and Mer–/– mice had 
a tendency to repetitively rebleed after transient hemostasis.
Figure 2
Loss of Tyro3, Axl, or Mer protects mice against thrombo-
sis. (A) Stasis-induced thrombosis in the inferior vena cava 
(mean ± SEM, n = 10). *P < 0.005. (B) Thromboembolism 
induced by collagen/epinephrine injection in WT (n = 15) and 
in Tyro3–/– (n = 15), Axl–/– (n = 10), and Mer–/– (n = 12) mice. 
*P < 0.005. (C and D) Light microscopy (H&E staining) of the 
lungs after collagen/epinephrine injection, revealing extensive 
platelet thromboemboli (arrows) in WT mice (C) but not in sur-
viving Axl–/– mice (D) or Tyro3–/– or Mer–/– mice (not shown). 
Scale bars: 100 μm.
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(2 μg/ml; Figure 3B), or U46619 (1 μM; Figure 3C), although higher 
concentrations of these agonists were capable of inducing irrevers-
ible aggregation of platelets (Figure 3, A–C). The impaired plate-
let aggregate formation in Gas6-R–deficient mice resulted from 
signaling defects most likely upstream of PKC activation or Ca++ 
mobilization, since WT, Tyro3–/–, Axl–/–, or Mer–/– platelets aggre-
gated normally in response to PMA or the Ca++ ionophore A23187 
(data not shown). Thrombin (0.01–1.0 IU/ml) and the protease-
activated receptor 4–activating (PAR4-activating) peptide AYPGKF 
(0.25–1.0 mM) (26) comparably stimulated initial platelet aggre-
gation in all genotypes (data not shown). However, clot retraction 
upon thrombin treatment was significantly impaired in Tyro3–/–, 
Axl–/–, or Mer–/– mice (Figure 4). These data establish a key role for 
the Gas6-Rs in the perpetuation of platelet activation and the sta-
bilization of platelet aggregates.
Normal fibrinogen binding in Tyro3–/–, Axl–/–, or Mer–/– platelets. Since 
binding of fibrinogen during initial platelet activation — a process 
that depends on inside-out signaling to αIIbβ3 (27) — is critical for 
platelet aggregation, we examined whether the platelet defect of 
Gas6-R–deficient mice was attributable to impaired fibrinogen 
binding. However, fibrinogen binding during initial platelet acti-
vation was similar in all genotypes. Indeed, platelets of all geno-
types bound comparable amounts of Oregon Green 488–conju-
gated fibrinogen after stimulation with various concentrations of 
ADP (1.25–20 μM; Figure 5). Thus, loss of a Gas6-R does not seem 
to affect the initial conversion of αIIbβ3 from a low-affinity/low-
avidity to a high-affinity/high-avidity receptor upon activation of 
platelets by various agonists.
Defective outside-in signaling in Tyro3–/–, Axl–/–, or Mer–/– platelets. To 
analyze platelet spreading after adhesion to fibrinogen (a process 
that depends on outside-in signaling via αIIbβ3), unstimulated 
platelets were incubated on a fibrinogen-coated surface. Nota-
bly, fewer platelets from Tyro3–/–, Axl–/–, or Mer –/– mice adhered 
to fibrinogen, and these failed to spread out as extensively as WT 
platelets during the first 15–30 minutes of incubation (Figure 6, 
A–D). However, after 60 minutes, a comparable number of plate-
lets from WT, Tyro3–/–, Axl–/–, or Mer –/– mice spread on fibrino-
gen-coated surface (Figure 6, E and F), indicating that spreading 
of mutant platelets was impaired but not permanently abrogated. 
Analysis by video microscopy revealed that Axl–/– platelets, once 
they adhered, required longer times to maximally spread than WT 
platelets (300 ± 23 seconds for Axl–/– platelets versus 160 ± 11 sec-
onds for WT platelets; n = 50, P < 0.05; Figure 7A). Moreover, when 
the cellular area of the platelets was measured at various times 
after spreading, Axl–/– platelets were smaller than WT platelets at 
any time point, which again indicated that platelet spreading was 
impaired in the absence of Axl (Figure 7B). These findings are in 
agreement with the impaired clot retraction observed with Tyro3–/–, 
Axl–/–, and Mer–/– platelet-rich plasma (PRP) clots (Figure 4).
Defective platelet secretion in Tyro3–/–, Axl–/–, or Mer –/– platelets. We 
previously documented a close correlation between the impaired 
aggregation and the secretion response of Gas6–/– platelets to vari-
ous agonists and therefore measured the secretion response of 
Tyro3–/–, Axl–/–, or Mer–/– platelets (7). Secretion of ADP from dense 
granules is essential for the formation of stable macroaggregates 
after initial formation of small, unstable platelet aggregates. This 
is accompanied by secretion of adhesion proteins such as fibrino-
gen, vWFa, and P-selectin from α granules, which further contrib-
utes to stable platelet plug formation. Secretion of dense-gran-
ule stores (evaluated by measurement of the amount of released 
Figure 4
Effect of the lack of Tyro3, Axl, or Mer on clot retraction. Photographs 
show the degree of clot retraction after 60, 90, and 120 minutes in 
WT, Tyro3–/–, Axl–/–, and Mer–/– PRP samples treated with 10 IU/ml 
thrombin. Tyro3–/–, Axl–/–, and Mer–/– PRP was slower than WT PRP in 
retracting clots (n = 3). Clots are surrounded by dotted lines.
Figure 3
Effect of the lack of Tyro3, Axl, or Mer on aggregation of WT, Tyro3–/–, 
Axl–/–, or Mer–/– PRP. (A) Response of WT or Tyro3–/– platelets to 5 μM 
and 50 μM ADP. (Similar results were obtained with Axl–/– and Mer–/– 
platelets; data not shown.) (B) Response of WT or Axl–/– platelets to 
2 μg/ml and 10 μg/ml collagen. (Similar results were obtained with 
Tyro3–/– and Mer–/– platelets; data not shown.) (C) Response of WT 
or Mer–/– platelets to 1 μM and 7 μM TXA2 analogue U46619. (Similar 
results were obtained with Tyro3–/– and Axl–/– platelets; data not shown.) 
(D) Aggregation response to ADP (5 μM) of washed human platelets 
after preincubation with human Axl extracellular domain (hAxl-EC-Fc) 
or control IgG, revealing that hAxl-EC-Fc reduces platelet aggregation. 
A representative example of 3 independent experiments is shown. 
Arrows in A–D indicate addition of the platelet agonists.
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ATP) in response to 2 μg/ml collagen was significantly impaired 
in Tyro3–/– platelets (9.9 ± 0.7 μM ATP from WT platelets versus 
5.3 ± 0.2 μM ATP from Tyro3–/– platelets; n = 3, P < 0.05). Secretion 
of α granules, assessed by measurement of the surface levels of 
P-selectin during platelet activation, was also impaired in Tyro3–/–, 
Axl–/–, or Mer–/– platelets in response to low concentrations of ADP 
(Figure 8). Thus, defects in granule secretion may also contribute 
to the phenotypes of Gas6-R deficiency.
Gas6 stimulates tyrosine phosphorylation of the β3 integrin. The above 
findings that Gas6-Rs regulate spreading of platelets on fibrinogen 
and stabilization of the platelet plug suggested that Gas6-R sig-
naling influenced outside-in signaling by the αIIbβ3 integrin. Upon 
ligand binding, critical tyrosine residues in the cytoplasmic tail of 
the β3 integrin become phosphorylated, which then serve as dock-
ing sites for downstream signaling molecules. We therefore inves-
tigated the effect of Gas6 on β3 integrin tyrosine phosphorylation 
by immunoblotting using anti-β3 [pY773] phosphospecific anti-
bodies. Since Gas6, by itself, is unable to promote platelet aggre-
gation (7), treatment of platelets with Gas6 permitted us to 
study αIIbβ3 tyrosine phosphorylation independently of platelet 
aggregation. As shown in Figure 9A, treatment of resting plate-
lets with Gas6 stimulated β3 integrin tyrosine phosphorylation in 
WT platelets. In contrast, such β3 tyrosine phosphorylation did 
not occur when Tyro3–/– (Figure 9A), or Axl–/– or Mer–/– (data not 
shown), platelets were treated with Gas6. The reduced β3 tyrosine 
phosphorylation in Gas6-R–deficient platelets was not attribut-
able to a decrease in total β3 integrin expression, as shown by flow 
cytometry (Figure 9B). Gas6-R signaling determined the degree 
of β3 phosphorylation not only in resting platelets, but also in 
activated platelets after stimulation with thrombin. Indeed, when 
WT platelets were stimulated with thrombin (which is known to 
enhance release of Gas6 from the endogenous platelet stores; see 
ref. 7), the β3 integrin became tyrosine-phosphorylated (Figure 
9C). Quantification by densitometry revealed that a lower per-
centage of the total amount of β3 was tyrosine-phosphorylated 
(30% ± 4% and 30% ± 4% in WT platelets versus 8% ± 2% and 
20% ± 2% in Tyro3–/– platelets after 0.05 and 0.10 IU thrombin/
ml, respectively; n = 3, P < 0.05). Absence of Gas6-R significantly 
reduced but did not, however, abolish tyrosine phosphorylation 
of the β3 integrin, as higher concentrations and longer times of 
application of thrombin did stimulate phosphorylation of the β3 
integrin (Tyro3–/–, Figure 9C; Axl–/– and Mer–/–, data not shown). 
Thus, Gas6-R signaling determines β3 tyrosine phosphorylation 
and, thereby, also outside-in signaling of αIIbβ3, defects of which 
result in retarded platelet spreading on fibrinogen.
Gas6 stimulates phosphorylation of its receptors. Since some of the 
effects of the Gas6-Rs have been proposed to be ligand-indepen-
dent and to not require tyrosine phosphorylation of the receptors 
(28), we analyzed whether Gas6 enhanced the kinase activity of 
Tyro3, Axl, and Mer. Immunoprecipitation using phosphotyrosine 
antibodies and subsequent immunoblotting using Gas6-R–specif-
ic antibodies revealed that Gas6 induced tyrosine phosphorylation 
of Tyro3 (data not shown), Axl (Figure 9A), and Mer (data not 
shown) in WT platelets. As expected, when a particular Gas6-R 
(for instance Axl) was absent, it could not be immunoprecipitated. 
Remarkably, however, absence of Tyro3 prevented ligand-induced 
tyrosine phosphorylation of the 2 other Gas6-Rs (Axl, Figure 9A; 
and Mer, data not shown). Similarly, when Axl or Mer was absent, 
Gas6-induced tyrosine phosphorylation of the residual Gas6-R 
failed to occur, suggesting that the Gas6-Rs cooperate in their 
activation response (see below).
As this might be due to interdependent expression patterns of each 
of the Gas6-Rs, we analyzed by flow cytometry the expression level of 
Gas6-Rs that are capable of binding Gas6, on the surface of resting 
platelets from WT mice or mice lacking any 1 of the Gas6-Rs. Plate-
lets were incubated with recombinant myc-tagged Gas6 (Gas6-myc), 
and binding of Gas6-myc was measured by flow cytometry using an 
anti-myc antibody. As shown in Figure 10, Gas6-myc was found to 
bind to WT platelets, while only negligible amounts of Gas6-myc 
bound to Tyro3–/–, Axl–/–, or Mer–/– platelets. These findings thus 
reveal that, in the absence of 1 Gas6-R subtype, the expression of 
the other Gas6-Rs is also minimal. To confirm that the expression 
of the Gas6-Rs was indeed regulated in an interdependent manner, 
we measured by flow cytometry, using an anti-Axl antibody, the 
expression level of Axl (as a prototype of the Gas6-Rs) on platelets. 
Figure 5
Effect of the lack of Tyro3, Axl, or Mer on fibrinogen binding. Loss of 1 
Gas6-R (results shown for Axl–/– mice) does not inhibit fibrinogen binding 
to αIIbβ3 integrin. The binding of labeled fibrinogen to platelets activated 
with ADP (1.25–20 μM) was measured by flow cytometry. Black lines 
denote resting platelets; red shading denotes ADP-stimulated platelets. 
A representative example of 4 independent experiments is shown.
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As expression of Axl on the surface of resting platelets was below the 
detection limit of this assay (data not shown), we stimulated platelets 
with the PAR4-activating peptide (0.25 mM). Activated WT platelets 
expressed detectable levels of Axl on their surface, while, as expected, 
Axl was absent from activated Axl–/– platelets (Figure 11). Notably, 
however, activated Tyro3–/– platelets and Mer–/– platelets expressed 
only minimal amounts of Axl on their surface (Figure 11). Simi-
lar results were obtained from analysis of the expression of Tyro3 
(platelets expressing Tyro3 in WT mice, 77% ± 4%; in Tyro3–/– mice, 
6% ± 0.5%; in Axl–/– mice, 38% ± 6%; and in Mer–/– mice, 34% ± 4%; 
mean ± SEM, n = 3, P < 0.05) or Mer (platelets expressing Mer in WT 
mice, 70% ± 3%; in Tyro3–/– mice, 39% ± 2%; in Axl–/– mice, 35% ± 3%; 
and in Mer–/– mice, 9% ± 0.6%; mean ± SEM, n = 4, P < 0.05). Thus, 
lack of any 1 of the Gas6-Rs signif-
icantly reduced the expression of 
the other Gas6-Rs on the surface 
of platelets and, thus, the capacity 
to bind and respond to activation 
by Gas6.
Gas6 signaling activates PI3K and 
Akt. The signaling pathway, down-
stream of Gas6-R activation, was 
further investigated. The Gas6 
pathway does not seem to influ-
ence the eicosanoid synthesis 
pathway, as Gas6–/– platelets pro-
duce normal amounts of TXA2 
(7) and Gas6-R signaling in other 
cell types requires PI3K and Akt 
(18–20). We therefore analyzed 
whether Gas6-R signaling might 
activate PI3K and Akt, as the 
PI3K pathway is involved in αIIbβ3 
activity regulation in platelets (4, 
29). Indeed, Gas6 was found to 
enhance phosphorylation of PI3K 
and Akt in resting WT platelets, 
but not in Tyro3–/– (Figure 9A), 
Axl–/–, or Mer–/– (data not shown) platelets, indicating that each 
Gas6-R is critical for signal transduction of Gas6. The Akt pathway 
is also well known to play a key role in response to thrombin. In 
WT platelets, Akt phosphorylation was already increased within 30 
seconds after activation with 0.05 IU/ml thrombin (Figure 12). In 
contrast, Akt phosphorylation in Tyro3–/–, Axl–/–, (data not shown), 
and Mer–/– (Figure 12, A and B) platelets occurred only after 3 min-
utes, and only when the platelets were stimulated with a 10-fold 
higher concentration of thrombin (0.5 IU/ml; Figure 12, A and B). 
Thus, phosphorylation of Akt was impaired in platelets lacking any 
1 of the Gas6-Rs.
The soluble Axl extracellular domain inhibits platelet function. We next 
assessed the therapeutic potential of blocking the Gas6-R–depen-
dent amplification of outside-in signaling via αIIbβ3 by using the 
soluble Axl extracellular domain (hAxl-EC-Fc), which traps Gas6. 
The aggregation of WT platelets in response to ADP (5 μM) was 
dose-dependently blocked by hAxl-EC-Fc. In contrast, hAxl-EC-Fc 
had no effect on WT platelets in the absence of ADP (Figure 3D). 
Administration of 0.75 mg/kg hAxl-EC-Fc significantly protected 
WT mice against fatal collagen/epinephrine–induced pulmonary 
thromboembolism. Indeed, 60% of the mice receiving hAxl-EC-Fc 
survived, whereas none of the mice receiving control vehicle sur-
vived (n = 7, P < 0.05). Mice treated with hAxl-EC-Fc did not spon-
taneously bleed, nor were their bleeding times prolonged (data not 
shown). These results indicate that inhibition of Gas6-R signaling 
by trapping of its ligand effectively prevents thrombosis.
Discussion
We recently reported that loss of Gas6 protected mice against 
pathological thrombosis by preventing the formation of stable 
platelet plugs during the perpetuation phase of platelet activation 
(7). The findings of the present study that we believe to be novel 
are: (a) each of the Gas6-Rs (Tyro3, Axl, and Mer) is necessary to 
transmit the platelet-stabilization effect of Gas6 in vitro, whereas 
absence of any of these Gas6-Rs protects mice against pathologi-
Figure 6
Delayed Tyro3–/–, Axl–/–, or Mer–/– platelet spreading on immobilized 
fibrinogen. WT or Mer–/– platelets (similar results were obtained with 
Tyro3–/– and Axl–/– platelets) were incubated on a fibrinogen-coated 
surface for 15 minutes (A and B), 30 minutes (C and D), and 60 min-
utes (E and F) without agonist and stained with rhodamine-phalloidin 
to visualize actin. A representative example of 3 independent experi-
ments is shown. Field width: 50 μm.
Figure 7
Effect of Axl deficiency on platelet spreading 
time and spreading area. (A) Spreading time 
after adhesion, recorded by video microscopy, 
was longer in Axl–/– than in WT platelets. Field 
width: 6 μm. (B) Platelet area measured using 
Openlab 3.0.6 software (Improvision) was 
smaller in Axl–/– than in WT mice.
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cal thrombosis in vivo; (b) Gas6-R signaling appears to affect out-
side-in signaling via the αIIbβ3 integrin and to regulate granule 
secretion; and (c) activation of Gas6-R by Gas6 activates PI3K and 
stimulates tyrosine phosphorylation of β3 integrin. These genetic 
studies provide novel insight into the poorly understood physi-
ological importance of outside-in signaling, which is critical for 
the formation of stable platelet plugs and clot retraction.
Gas6-R–/– mice are phenocopies of Gas6–/– mice. Mice lacking any 1 of 
the 3 Gas6-Rs (Tyro3, Axl, or Mer) have nor-
mal initial bleeding times and are resistant to 
thrombosis, but they do not suffer spontane-
ous bleeding. Their resistance to thrombosis 
was not due to impaired megakaryocytopoi-
esis or defects in the coagulation cascade 
but was due, at least in part, to platelet dys-
function. As Gas6 seems to regulate also 
the expression of tissue factor on activated 
endothelial cells (E.M. Conway and P. Car-
meliet, unpublished observations), we can-
not exclude the possibility that Gas6-Rs also 
contribute to thrombus formation via such 
a mechanism. However, the platelet transfu-
sion experiments clearly indicate that the 
antithrombotic phenotype in Gas6-R–defi-
cient mice is, at least in part, attributable to 
a platelet defect. In the absence of a Gas6-R, 
low concentrations of ADP, collagen, or TXA2 
induced reversible platelet aggregation, while 
high concentrations of these platelet agonists 
caused irreversible platelet aggregation. In 
addition, low concentrations of thrombin or 
the PAR4-activating peptide stimulated plate-
let aggregation. Thus, aggregation of platelets 
could occur but was less efficient in platelets 
lacking any 1 of the Gas6-Rs. Irreversible 
aggregation of Gas6-R–deficient platelets 
required higher concentrations of platelet 
agonists or a potent agonist such as throm-
bin. Thus, Gas6-R–/– mice are phenocopies of 
Gas6–/– mice (7). Overall, the antithrombotic 
effect of the lack of Gas6 or a Gas6-R is com-
parable to that of aspirin, when assayed in the 
same thromboembolism model (30).
A remarkable finding was, however, that deficiency of any of the 
Gas6-Rs protected mice against thrombosis to the same signifi-
cant extent, which suggests that each of these receptors has a com-
parably important role in platelet aggregation. Even more, Gas6 
was capable of inducing tyrosine phosphorylation of each Gas6-R, 
but absence of 1 Gas6-R prevented tyrosine phosphorylation of 
the 2 other Gas6-Rs. An explanation for the latter phenomenon is 
provided by the observation that substantial amounts of Gas6-R 
reached the platelet surface only during platelet activation and that 
the lack of any 1 of the Gas6-Rs dramatically reduced the surface 
expression of the other receptors. As a result, the binding of Gas6 
to Gas6-Rs on the platelet surface was significantly reduced to neg-
ligible residual levels when 1 of these Gas6-Rs was absent. These 
findings suggest that Gas6-Rs somehow cross-talk to each other 
to codetermine their surface exposure and responsiveness to Gas6 
(i.e., binding of ligand, stimulation of receptor tyrosine kinase 
activity). Thus, the exposure of any 1 of the Gas6-Rs appears to 
Figure 9
Gas6 signaling through its receptors Tyro3, Axl, and Mer. (A) Gas6 promotes phosphorylation 
of its receptors (shown for Axl), PI3K, Akt, and β3 integrin in WT but not in Tyro3–/–, Axl–/– (not 
shown), or Mer–/– (not shown) platelets. Platelets were incubated with 400 ng/ml human recom-
binant Gas6 (hrGas6) for 3 minutes. For detection of Axl or PI3K phosphorylation, platelets were 
lysed and phosphotyrosine-containing proteins were immunoprecipitated. The precipitates were 
then separated by SDS-PAGE and Western-blotted (WB) with anti-Axl or anti-PI3K antibodies. 
For Akt and β3 integrin phosphorylation studies, lysed platelets in sample buffer were subjected 
to SDS-PAGE and Western-blotted with anti–phospho-Akt antibody, anti–total Akt antibody, 
anti–β3 integrin [pY773] phosphospecific antibody, or anti–β3 integrin antibody. (B) β3 Integrin 
levels measured by flow cytometry were comparable on the surface of WT and Tyro3–/–, Axl–/–, or 
Mer–/– platelets (only Tyro3–/– data are shown). Black lines denote controls; red shading denotes 
platelets stained with PE-conjugated anti–β3 integrin antibody. A representative example of 
3 independent experiments is shown. (C) β3 Integrin tyrosine phosphorylation in response to 
thrombin in WT and Tyro3–/– platelets. Platelets were stimulated with increasing concentrations 
of thrombin for 3 minutes. A representative example of 3 independent experiments is shown.
Figure 8
Effect of the absence of Tyro3, Axl, or Mer on P-selectin expression, a 
marker of α granule secretion. Analysis by flow cytometry revealed that 
P-selectin levels on the platelet surface were significantly reduced in 
Tyro3–/–, Axl–/–, or Mer–/– platelets, after activation with ADP. Black lines 
denote resting platelets; red shading denotes ADP-stimulated platelets. 
A representative example of 3 independent experiments is shown.
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be regulated by each of the others. While the present data indicate 
that each Gas6-R has a significant role in hemostasis on its own 
(other gene-inactivation studies also indicated that loss of a single 
Gas6-R can lead to a significant phenotype; see refs. 31, 32), our 
data obviously do not exclude the possibility that these Gas6-Rs 
might cooperate in an additive manner, as they do in the regula-
tion of spermatogenesis and innate immunity (21, 33). In fact, the 
experimental conditions used here were not set up to unveil an 
additive or synergistic interaction. Genetic intercrosses among the 
Gas6-R–deficient mice, in combination with more severe throm-
botic models, might allow us to address these outstanding ques-
tions in the future.
Absence of a Gas6-R impairs outside-in signaling. Platelets lack-
ing Tyro3, Axl, or Mer bound normal amounts of fibrinogen in 
response to ADP. While these findings are consistent with a model 
whereby Gas6-R signaling would not be necessary for initial acti-
vation of αIIbβ3 by inside-out signaling, the present data do not 
exclude the possibility that Gas6-R signaling might modulate this 
process at a later stage. In fact, our data indicate that the Gas6-R 
signaling was required for tyrosine phosphorylation of the β3 
integrin and thus for outside-in αIIbβ3 signaling. Such a model 
also explains why mice lacking any 1 of the Gas6-Rs had a tenden-
cy to rebleed after transient hemostasis and had delayed platelet 
spreading and clot retraction, processes consistent with a defect 
in regulation of outside-in αIIbβ3 signaling (1). The platelet dys-
function caused by absence of a Gas6-R resembles that of mice in 
which the cytoplasmic tyrosine residues of the β3 integrin subunit 
were mutated to phenylalanine (DiYF mice) (2). Both DiYF mice 
and Gas6-R–deficient mice exhibit normal fibrinogen binding and 
a normal first wave of ADP-induced platelet aggregation. In con-
trast, outside-in signaling in DiYF and Gas6-R–deficient platelets 
was impaired, as they spontaneously disaggregated following ini-
tial aggregation in response to ADP. Both strains also had defective 
clot retraction upon thrombin treatment and showed a tendency 
to rebleed after initial cessation of bleeding. A difference between 
the DiYF and the Gas6-R–deficient phenotypes is that Gas6-R–
deficient platelets were able to overcome their defect when stimu-
lated by a high dose of platelet agonists for a long duration; this 
indicates that the absence of a Gas6-R caused a milder outside-in 
signaling defect than the DiYF mutation did. Our findings obvi-
ously do not exclude the possibility that Gas6-R signaling might 
be involved in additional mechanisms, regulating platelet plug 
stability and clot retraction. In fact, our data that Gas6-Rs also 
regulate the process of secretion from dense and α platelet gran-
ules and activate PI3K and Akt could imply that perpetuation of 
the platelet plug might be amplified by upregulation of β3 integrin 
activity, leading to enhanced platelet aggregate stability.
Gas6-R signaling. Activation of the Gas6-Rs stimulated 
phosphorylation of PI3K and Akt (34). PI3K plays an important role 
in strengthening platelet aggregation during the irreversible phase of 
aggregation (35, 36). Taken together, our data are consistent with a 
model whereby Gas6, secreted by activated platelets, amplifies fibrin-
ogen-induced platelet spreading, irreversible platelet aggregation, and 
clot retraction by inducing signals that lead to phosphorylation of 
Gas6-Rs, which in turn activate PI3K and Akt. How serine and threo-
nine phosphorylation, and subsequently tyrosine phosphorylation 
of the cytoplasmic tail of β3 integrin, are precisely modulated via 
Gas6-R activation remains to be further investigated but might 
involve intermediate activation of PI3K and Akt in association with 
integrin-linked kinase displacement toward αIIbβ3 (4).
Gas6/Gas6-R signaling: a novel class of platelet modifiers. Deficiency 
of the β3 integrin (37, 38), of either of the purinergic receptors 
P2Y1 (39, 40) and P2Y12 (41), of the GTP-binding Gαq (42), or 
of protease-activated receptor 3 (PAR3) or PAR4 (26, 43) protects 
mice against thrombosis but also causes bleeding. Deficiency of 
Gas6 or any of its receptors also protected mice against throm-
bosis but did not prolong the bleeding time after tail clipping. In 
this respect, the effect of Gas6-R signaling resembles that of Eph 
kinases and ephrins (5) and CD40 ligand (44). Whereas Gas6 by 
itself is not able to promote platelet aggregation (7), Gas6 signal-
Figure 10
Effect of the absence of Tyro3, Axl, or Mer on Gas6 binding. Analysis 
by flow cytometry revealed that binding of myc-tagged recombinant 
Gas6 to resting platelets was significantly lower in Tyro3–/–, Axl–/–, or 
Mer–/– than in WT platelets. Black lines denote negative control (PBS); 
red shading denotes binding of myc-tagged Gas6, detected by FITC-
conjugated anti–myc-tag antibody. A representative example of 3 inde-
pendent experiments is shown.
Figure 11
Axl expression on the surface of WT, Tyro3–/–, Axl–/–, or Mer–/– plate-
lets, activated by the PAR4-activating peptide AYPGKF (0.25 mM). 
Flow cytometry revealed that surface expression of Axl was dramati-
cally reduced in platelets lacking any 1 of the Gas6-Rs as compared 
with WT platelets. Axl expression was not detected on the surface of 
activated Axl–/– platelets. Black lines denote isotype-matched control; 
red shading denotes Axl. A representative example of 3 independent 
experiments is shown.
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ing is critical for platelet function during the late phase of platelet 
activation, when platelets come into close contact with each other. 
Gas6 perpetuates platelet activation by enhancing PI3K, Akt, gran-
ule secretion, and β3 integrin signaling. Gas6 thus belongs to a 
class of molecules that are redundant for base-line hemostasis but 
that constitute an important “amplification” system in pathologi-
cal conditions. Abnormal Gas6 signaling through 1 or several of its 
receptors might contribute to bleeding disorders due to a platelet 
dysfunction. Conversely, abnormal activation of the Gas6 pathway 
might also contribute to disease phenotypes due to platelet activa-
tion (e.g., heparin-induced thrombocytopenia, anti-phospholipid 
antibody syndrome) that are characterized by thrombosis. A very 
recent study indicates a significant association between a Gas6 
polymorphism and ischemic stroke, placing Gas6 as a promising 
candidate for a susceptibility gene for this disease (45).
Medical implications. Based on the critical role of αIIbβ3 in platelet 
function, pharmacological inhibitors of ligand binding to αIIbβ3 have 
been developed to prevent thrombosis. With the exception of recom-
binant antibodies that block fibrinogen binding to αIIbβ3 and there-
fore aggregation as well as outside-in signaling, all currently available 
antiplatelet drugs are specific inhibitors of inside-out signaling. For 
example, aspirin inhibits COX-1 and, consequently, the production 
of TXA2, while clopidogrel antagonizes signaling through the P2Y12 
receptor (46). Drugs designed to prevent irreversible platelet aggre-
gation rather than inhibition of formation of platelet aggregates 
are currently not available. Our findings indicate that inhibition 
of Gas6, involved in the signaling pathways controlling irreversible 
aggregation, could be a novel treatment paradigm. Indeed, a soluble 
Axl extracellular domain protected mice against fatal thromboembo-
lism without bleeding side effects. Axl extracellular domain therefore 
provides a novel and relatively safe means to prevent thrombosis.
Methods
Materials. Busulfan, ADP, U46619, and A23187 were from Sigma-Aldrich. 
Collagen was from Hormon Chemie. The PAR4 agonist peptide AYPGKF 
was synthesized by Bachem AG.
Mice. Tyro3–/–, Axl–/–, and Mer–/– mice were progeny of the original colony 
of 50% 129/50% C57BL/6 mice (21). WT mice used as controls had the same 
genetic background. Ethical approval for the animal experiments detailed 
in this article was received from the Institutional Animal Care and Research 
Advisory Committee of the University of Leuven and the Ethical Committee 
for Animal Experiments of the Medical Faculty of the University of Geneva.
Hemostasis. We measured bleeding by 2-mm tail-tip transection in mice 
anesthetized by i.p. injection of a mixture of ketamine (80 mg/kg) and 
xylazine (16 mg/kg). We used 2 models of bleeding time. For the first 
model, a stopwatch was started immediately upon transection to deter-
mine time to cessation of bleeding. Blood drops were removed every 30 
seconds using a filter paper. If bleeding did not recur within 60 seconds of 
cessation, bleeding was considered stopped. The second model was used 
to detect rebleeding after initial hemostasis. For quantitative estimation 
of the amount of blood loss per time unit after tail transection, the cut 
end of the tail was immediately immersed in 20 ml normal saline at 37°C. 
Aliquots of saline solution containing blood were sampled every minute 
for 10 minutes and then every 5 minutes until 30 minutes. Red blood cells 
were lysed using Zap-Oglobin II lytic reagent (Beckman Coulter Inc.), and 
samples were read at 405 nm (to measure the hemoglobin content). A 
quantitative estimation of the amount of blood loss was determined by 
measurement of the hemoglobin content of aliquots of blood collected 
in saline after tail transection as compared with known volumes of blood 
from the same mouse diluted in the same amount of saline.
Human recombinant Gas6 and Axl extracellular domain. Human recombinant 
Gas6 was produced in a human embryonic kidney cell line (HEK293) stably 
transfected with the pSecTag2/Hygro expression vector (Invitrogen Corp.) 
encoding the human Gas6 cDNA. Human recombinant Gas6 was puri-
fied from conditioned medium using a modification of a calcium affinity 
method used for proteins containing γ-carboxy-glutamic acid residues (47, 
48). The cDNA encoding a 415-AA mature human Axl extracellular domain 
(hAxl-EC) was cloned from a human kidney cDNA library (Stratagene). 
Splice overlap extension was used to fuse the cDNA downstream of the 
secretion signal of the pSecTag2/Hygro vector (Invitrogen Corp.), fol-
lowed by in-frame sequence coding for the human IgG-Fcγ (R&D Systems 
Inc.). The resulting expression vector drives expression and secretion of a 
hAxl-EC-Fc fusion under the control of the CMV promoter. The plasmid 
pSecTag2/Hygro–hAxl-EC-Fc was stably transfected in HEK293 cells. The 
hAxl-EC-Fc was purified on protein A-Sepharose.
Thrombosis models. Mice were anesthetized by i.p. injection of a mixture of 
ketamine (80 mg/kg) and xylazine (16 mg/kg). Thrombus formation due to 
stasis was induced by injection of tissue thromboplastin (1 vol Innovin/49 
vol saline; Innovin was from Dade Behring Inc.) into the dorsal vein of 
the penis (5 ml/kg), followed immediately by tightening of 1 suture in the 
inferior vena cava just below the left renal vein for 15 minutes. Thrombosis 
was quantified by weighing of the thrombus (49). In mice anesthetized by 
i.p. injection of sodium pentobarbital (60 mg/kg), thromboembolism was 
induced by injection of a mixture of collagen (0.5 mg/kg, equine collagen; 
Hormon Chemie) and epinephrine (60 μg/kg) into the jugular vein (30). 
When indicated, mice received 10 μg hAxl-EC-Fc.
Platelet aggregation. Platelet aggregation was performed as described in 
ref. 7. Briefly, whole blood, drawn from anesthetized mice from the inferior 
vena cava into 3.13% citrate (1 vol anticoagulant/9 vol blood), was centri-
fuged at 100 g (10 minutes) to obtain PRP and additionally at 2,000 g (10 
minutes) to obtain platelet-poor plasma (PPP). PRP and PPP were pooled 
from 4–6 mice. To prepare washed platelets, apyrase was added to PRP 
(final concentration, 1 IU/ml), and platelets were incubated for 10 min-
utes at 37°C, washed by addition of 2 vol acid-citrate-dextrose solution 
(22 g trisodium citrate dihydrate, 8 g citric acid monohydrate, and 25 g 
glucose dextrose in 1 liter of H2O), and centrifuged at 2,000 g (10 minutes). 
The platelet pellet was resuspended in Tyrode’s buffer (pH 7.3) containing 
137 mM NaCl, 2.7 mM KCl, 12 mM NaHCO3, 0.4 mM NaH2PO4, 5 mM 
HEPES, and 0.1% BSA. CaCl2 (2 mM final) and MgCl2 (1 mM final) were 
added immediately before platelet stimulation. Platelet aggregation was 
Figure 12
Akt phosphorylation in response to thrombin in WT and Mer–/– plate-
lets. (Similar results were obtained with Tyro3–/– and Axl–/– platelets; 
data not shown.) (A) Platelets were stimulated with increasing concen-
trations of thrombin for 3 minutes. (B) Time course of 1 IU/ml thrombin. 
A representative example of 3 independent experiments is shown.
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measured turbidimetrically using an optical Platelet Aggregation Profiler 
(model PAP-4; Bio/Data Corp.). When indicated, WT washed platelets were 
preincubated with hAxl-EC-Fc before stimulation with ADP (1 minute).
Clot retraction. PRP was diluted with PPP to bring the platelet count to 100 
G/l and put into an aggregation cuvette. Thrombin was added at a final con-
centration of 10 IU/ml. The aggregation cuvette was then incubated at 37°C 
in the aggregometer for 2 hours without stirring, while the clot retraction 
was monitored every 15 minutes (N. Prévost, unpublished observations).
Fibrinogen binding. Washed platelets (108/ml in final volume) were incubat-
ed simultaneously with a mixture of PBS (negative control) or ADP (1.25–20 
μM in final volume), Oregon Green 488–conjugated fibrinogen (150 μg/ml 
in final volume; Invitrogen Corp.), and Tyrode’s buffer containing 0.1% BSA 
in a final volume of 200 μl. After 10 minutes at 37°C under stirring condi-
tions, samples were fixed by the addition of paraformaldehyde (1% in final 
volume). Platelets were then resuspended in 500 μl PBS containing 0.2% BSA, 
and samples were analyzed by flow cytometry using a FACScan instrument 
(BD Biosciences) and CellQuest software (BD Biosciences).
Platelet secretion. Dense-granule secretion, investigated by platelet ATP 
release in response to collagen, was monitored in PRP by addition of firefly 
luciferase and luciferin and comparison of the luminescence generated by 
platelet ATP release with that generated by an ATP standard (CHRONO-
LUME; Chrono-Log Corp.), as reported previously (7). To measure α gran-
ule secretion, washed platelets (108/ml) were incubated with ADP at vari-
ous concentrations for 10 minutes at 37°C under stirring conditions and 
subsequently labeled with FITC-conjugated anti–P-selectin antibody (BD 
Biosciences — Pharmingen) and analyzed by flow cytometry using a FACScan 
instrument and CellQuest software, as described previously (7).
Adhesion to immobilized fibrinogen. Adhesion to immobilized fibrinogen was 
quantified as described previously (50). Human fibrinogen (Sigma-Aldrich) 
in PBS (pH 8.0) was plated onto microtiter plates at concentrations ranging 
from 1 ng to 2 μg per well and incubated overnight at 4°C. Plates were washed 
twice with PBS (pH 7.4) and blocked for 2 hours at room temperature with 20 
mg/ml BSA in PBS. Fifty microliters of washed platelets (6 × 106) in Tyrode’s 
buffer containing 0.1% BSA was added per well. After 1 hour of incubation, 
nonadherent platelets were removed, and the wells were washed twice with 
150 μl Tyrode’s buffer supplemented with 1 mM MgCl2. One hundred fifty 
microliters of pNpp buffer (0.1 M citrate [pH 5.4], 0.1% Triton X-100, 5 mM 
para-nitrophenylphosphate) was added for 1 hour at room temperature. 
Then, 100 μl of 2-M NaOH was added, and adherent platelets were quanti-
fied in a microplate reader at 405 nm. The percentage of platelets adhering 
was determined by calculation of the ratio of bound to maximal signal at 405 
nm, where maximal reading was obtained from a microtiter well containing 
6 × 106 platelets that was not subjected to washing procedures.
Rhodamine-phalloidin staining. A Lab-Tek chamber slide (Nalge Nunc Inter-
national) was coated with 100 μg/ml fibrinogen. Washed platelets (6 × 106) 
in Tyrode’s buffer supplemented with CaCl2 and MgCl2 were added to each 
well of the chamber slide for 15–60 minutes at 37°C. Nonadherent platelets 
were washed away, and adherent cells were fixed in 1% paraformaldehyde in 
PBS for 15 minutes at room temperature. After 3 washes with PBS, excess 
aldehyde was quenched with 10 mM ethanolamine in PBS (or 0.1 M glycine 
in PBS) for 5 minutes. Platelets were permeabilized in 0.1% Triton X-100 in 
PBS for 1 minute and incubated in rhodamine-phalloidin (Sigma-Aldrich) 
diluted 1:100 in PBS for 15 minutes. The slide was removed from the cham-
ber and then washed 3 times in PBS. Slides were then mounted in VECTA-
SHIELD (Vector Laboratories Inc.). Platelet spreading was analyzed with an 
Axiophot microscope equipped with an AxioCam camera (Carl Zeiss AG).
Platelet-spreading analysis by video microscopy. Observation chambers coated 
with human fibrinogen in PBS (pH 8.0) (2 mg/ml) were washed twice with 
PBS (pH 7.4) and blocked for 2 hours at room temperature with 20 mg/ml 
BSA in PBS. Then, washed platelets resuspended in Tyrode’s buffer (105) 
were dropped into the chambers and observed with an Axiovert 100 TV 
inverted microscope (Carl Zeiss AG), equipped with a heated stage (37°C) 
and a digital charged-coupled device camera (C4742-95-10; Hamamatsu 
Photonics). Platelet spreading was recorded with Openlab 3.0.6 software 
(Improvision) with frame intervals of 15–30 seconds.
Immunoprecipitation and Western blotting. For immunoprecipitation, 
washed platelets were lysed in the presence of the following protease inhibi-
tors: 1 μM NaVO4, 1 mM NaF, and complete inhibitors (Roche Diagnostics 
Corp.). Insoluble materials were removed by centrifugation for 10 minutes 
at 4°C. The resulting supernatants were immunoprecipitated with mono-
clonal anti-phosphotyrosine–agarose (clone PT-66) beads (Sigma-Aldrich). 
For dose-response and time-course experiments, stirred washed platelets 
(4 × 108 platelets in 100 μl Tyrode’s buffer) were stimulated with human 
recombinant Gas6 or thrombin at 37°C. The reaction was stopped by the 
addition of SDS sample buffer. Sample aliquots were loaded on SDS-PAGE 
(10%) and subjected to Western blotting using 1 of the following antibod-
ies: anti-Rse (also called Tyro3), anti-Axl, anti-Mer, anti–PI3K p85α, anti–β3 
integrin (Santa Cruz Biotechnology Inc.), the PhosphoPlus Akt (Ser473) 
antibody (Cell Signaling Technology Inc.), or anti–β3 integrin [pY773] phos-
phospecific antibody (Biosource International Inc.). The data are repre-
sentative of 3–4 independent experiments using PRP pooled from 6 WT, 
Tyro3–/–, Axl–/–, or Mer–/– mice.
Detection of β3 integrin on platelet surface by flow cytometry. Washed platelets 
(108/ml) were incubated with PE-conjugated anti–β3 integrin antibody 
(BD Biosciences — Pharmingen) and analyzed by flow cytometry using a 
FACScan instrument and CellQuest software.
Gas6 binding. Washed platelets (108/ml in final volume) were incubated 
simultaneously with PBS (negative control) or myc-tagged recombinant 
Gas6 (5 μg/ml in final volume) and FITC-conjugated anti–myc-tag anti-
body (Abcam Ltd.) in Tyrode’s buffer containing 0.1% BSA in a final volume 
of 200 μl at 37°C for 10 minutes under stirring conditions. The reaction 
was stopped by the addition of paraformaldehyde (1% in final volume), and 
platelets were resuspended in 500 μl PBS containing 0.2% BSA and analyzed 
by flow cytometry using a FACScan instrument and CellQuest software.
Detection of Gas6-R on platelet surface by flow cytometry. Resting washed plate-
lets (108/ml in final volume) or washed platelets activated by the PAR4-acti-
vating peptide AYPGKF at 0.25 mM for 10 minutes at 37°C under stirring 
conditions were incubated with an anti-Tyro3, an anti-Axl, or an anti-Mer 
antibody (R&D Systems Inc.). Tyro3, Axl, or Mer was subsequently detected 
on platelets by a FITC-conjugated rabbit anti-rat antibody and analyzed by 
flow cytometry using a FACScan instrument and CellQuest software.
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